PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-272.88%
Both yoy net incomes decline, with GNPX at -17.92%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
77.92%
D&A growth of 77.92% while GNPX is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
100.00%
Deferred tax of 100.00% while GNPX is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
49.65%
SBC growth while GNPX is negative at -51.17%. John Neff would see competitor possibly controlling share issuance more tightly.
56.13%
Less working capital growth vs. GNPX's 193.21%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
59.43%
A yoy AP increase while GNPX is negative at -231.79%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-0.47%
Negative yoy usage while GNPX is 214.13%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
85.22%
Growth of 85.22% while GNPX is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might reflect intangible expansions or partial write-offs.
-64.88%
Negative yoy CFO while GNPX is 7.14%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
82.30%
CapEx growth of 82.30% while GNPX is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
82.30%
We expand invests by 82.30% while GNPX is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
-39.13%
We cut debt repayment yoy while GNPX is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-90.34%
Both yoy lines negative, with GNPX at -71.09%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.